UPDATED: GSK, Vir barrel into a fast PhII/III for their lead Covid-19 antibody, chasing a moving target with quick OK in sight –

Now that Eli Lilly and Regeneron have strayed off schedule on the development of new antibodies to fight Covid-19, GlaxoSmithKline execs and their partners at Vir are jumping into the clinic. And they say they could have the first data cut ahead of the end of this year, with late-stage

Sourced through Scoop.it from: endpts.com